PTP4A3 Is a Prognostic Biomarker Correlated With Immune Infiltrates in Papillary Renal Cell Carcinoma

PTP4A3 vervult een essentiële functie binnen de tumorvorming en metastase van een aantal tumoren , maar de prognostische functie ervan bij de meeste nierkankers zal niet effectief worden begrepen. We gebruik gemaakt van de Oncomine en Tumor Immunoassay Nuttig resource databases te kijken naar de differentiële expressie van PTP4A3 in tumor weefsels en regelmatige weefsels in de borst, urinewegen, maagdarmkanaal en poriën en de huid.

Gebruik makend van de GEPIA en PrognoScan databases, de onpartijdige prognostische functie van PTP4A3 werd bevestigd in clear cell niercelcarcinoom meeste vormen van kanker en papillaire niercelkanker meeste vormen van kanker . Expressie van PTP4A3 was duidelijk groter in tumorweefsel , te evalueren met reguliere weefsels ( P = 0,028).

We hebben de associaties van PTP4A3 en klinisch-pathologische opties niet ontdekt in ons IHC- cohort. Ectopische expressie van PTP4A3 bevordert proliferatie, migratie en invasie en verhoogde het mRNA-stadium van TGFB1 in RCC-celstammen.

Immunohistochemische kleuring gaf aan dat de expressie van PTP4A3 associeert met CD3 + ( P = 0,037) / CD8 + ( P = 0,037) intra tumor TIL, niet met invasieve marges renale kanker . Volledige evaluatie van immuuninfiltratie in de TIMER-database correleerde PTP4A3-expressie met de infiltratie van B-cellen, CD8+ T-cellen, CD4+ T- cellen en neutrofielen in elk heldercellig niercelcarcinoom en papillair niercelcarcinoom.

PTP4A3-expressie was gerelateerd aan de infiltratie van dendritische cellen in papillair niercelcarcinoom. We bevestigden bovendien dat de infiltratie van B-cellen en CD8+ T-cellen gerelateerd was aan een slechte prognose bij patiënten met papillair niercelcarcinoom, in overeenstemming met de prognostische functie van PTP4A3 bij papillair niercelcarcinoom.

PTP4A3-expressie correleerde genen in B-cellen, monocyten, M1-macrofagen, Th2- en Treg-cellen in papillair niercelcarcinoom. Deze uitkomsten raden PTP4A3 aan als een prognostische kwestie met een baan bij het reguleren van de infiltratie van immuuncellen bij papillair niercelcarcinoom.

hnRNPA2B1 bevordert de dikke darm De meeste kankers Ontwikkeling via de MAPK-route

HNRNPA2B1, een RNA bindend eiwit, vervult een belangrijke functie in grote microRNA verwerking, verschillende splicing, mRNA metabolisme en transport. Merkwaardig , hnRNPA2B1 bovendien werkt als N6-methyladenosine (M6A) lezer en is essentieel gedurende tumorgenese van diverse weefsels variëteiten .

Niettemin , zijn functie in de dikke darm kanker blijft onduidelijk. Bij dit onderzoek wilden we de organische mogelijkheden van hnRNPA2B1 ophelderen en de onderliggende mechanismen ervan ontdekken bij de meeste kankers in de dikke darm . We onderzochten de expressie van hnRNPA2B1 in Oncomine- en TCGA-databases.

Verifieerde vervolgens de bevindingen in de meeste kankercellen van de dikke darm en medische monsters met western blotting en immunohistochemie ( IHC ). We gebruikten CRISPR / Cas9 gerichte gen verhogen knockout hnRNPA2B1 expressie in humane colon kanker cellijn SW480 en HCT-116 en uitgevoerd elke in vivo en in vitro experimenten. De resultaten zijn bovendien bevestigd door RNA-seq-analyses.

We ontdekten dat hnRNPA2B1 aanzienlijk bevorderd dikke darm kanker celproliferatie elk in vitro en in vivo , terwijl knock-out van hnRNPA2B1 geïnduceerde apoptose en celcyclus arrestatie in SW480. RNA-seq-analyses onthulden dat de ERK / MAPK-route werd geactiveerd door hnRNPA2B1-upregulatie.

Naast , elke hnRNPA2B1 en MAPK route is geactiveerd medische colon kanker specimens en positief gecorreleerd. Mechanistisch gezien leek hnRNPA2B1 een stroomopwaartse regulator van de ERK/MAPK-route te zijn en remming van MAPK-signalering blokkeerde de gevolgen van hnRNPA2B1.

Taken collectief , onze gegevens blijkt dat de RNA-bindende eiwit hnRNPA2B1 stimuleert celproliferatie en reguleert celcyclus en apoptose van menselijke colon kanker door activering van de ERK / MAPK -signalering, die presenteren een nieuwe waarneming in geval van hnRNPA2B1 als een mogelijke therapeutisch doel voor de remedie van de meeste kankers van de dikke darm .

Metaplastisch borstcarcinoom: klinisch-pathologische parameters en prognostisch profiel

Inleiding Metaplastisch borstcarcinoom (MBC) wordt geschetst als de meeste borstkankers met een heteroloog niet-glandulair element . MBC houdt rekening met een bepaald soort borstkanker, de meeste kankers met een prognose die slechter is dan invasief ductaal carcinoom (IDC) van de borst. MBC is de meest typische borsten meeste vormen van kanker met een triple-negatieve profiel.

Vanwege dit feit , op deze onderzoeken , evalueerden we tot de klinische parameters, herhaling en overleving van MBC in onze inwoners . Strategieën We voerden een retrospectief observationeel onderzoek uit binnen de afdeling Histopathologie van het Prince Faisal Oncology Centre, Buraidah, Saoedi-Arabië, over een interval van 5 jaar.

Alle omstandigheden geïdentificeerd als MBC zijn opgenomen in het te onderzoeken . Oestrogeenreceptor (ER), progesteronreceptor (PR) en epidermale humane ontwikkeling probleem receptor 2 (HER2 / neu) immunohistochemie ( IHC ) werd uitgevoerd op consultant weefsel blokken. Uitkomsten Whole 183 omstandigheden van MBC’s zijn opgenomen in het onderzoek , waarvan 120 omstandigheden zijn excisie specimens.

De impliciete leeftijd van de patiënten was 48,84 ± 12,99 jaar, en de meest typische leeftijdsgroep was tussen 36 en 50 jaar. Veel van de omstandigheden waren tumor (T) stadium T3 (50%), en nodale metastase was actueel in 40% van de omstandigheden .

De meeste omstandigheden waren graad III (78,7%). ER-, PR- en HER2/neu-positiviteit was beroemd in respectievelijk 15,8%, 13,1% en 9,8%. Observatie-informatie is al 70 omstandigheden beschikbaar, met een mediane follow-up-interval van 4 (1-7) jaar. Tumorrecidief was beroemd in 31,4% omstandigheden, met een overlevingspercentage van 71,4%. Plaveiselcel, chondroïde, spilceldifferentiatie en matrixproductie zijn beroemd in respectievelijk 70,5%, 7,1%, 13,7% en een paar,2% omstandigheden.

Een belangrijke verwantschap van squameuze differentiatie was beroemd met HER2 / neu-positiviteit. Een omgekeerde verwantschap van spilceldifferentiatie werd gezien bij okselmetastasen. Survival evaluatie door Kaplan-Meier onthulde een grote aansluiting van de overleving met tumor recidief.

Conclusie MBC is een essentieel subtype van de meeste borstkankers , waarvan histopathologische identificatie moeilijk is vanwege verschillende histologische differentiatie. We ontdekten dat squameuze differentiatie de meest typische is in MBC, wat gerelateerd was aan HER2 / neu-positiviteit. Een buitensporig recidief van MBC werd bovendien opgemerkt in ons onderzoek dat aanzienlijk verband hield met overleving.

SOX9 is gerelateerd aan superieure T-stadia van medisch stadium II colon, de meeste kankers bij jongere Mexicaanse patiënten

De meeste colorectale kankers (CRC) is zonder twijfel een van de meest voorkomende maligniteiten ter wereld en bevat de meeste kankers van de dikke darm (CC) en de meeste rectale kankers (RC). Betreffende CC geval van nieuwe moleculaire biomarkers voor correcte analyse en prognose, naast de identificatie van nieuwe doelwitten voor therapeutische interventie, dringend gezocht .

SRY-verwante groep hoge mobiliteit veld 9 (SOX9), een transcriptie probleem wordt betrokken bij groei , en is gerelateerd aan de ontwikkeling van humane kanker . Niettemin , de onderliggende medische en bruikbare resultaten in CRC niet zijn helemaal begrepen. Vanwege dit feit was het huidige onderzoek gericht op het beoordelen van de medische en bruikbare relevantie van SOX9-expressie in CC.

De expressie van SOX9 in tumor weefsel werd geëvalueerd in 97 biopten van Mexicaanse patiënten met CC met een vroeg stadium I en II ziekte door middel van immunohistochemie ( IHC ). Evenals werd SOX9-silencing binnen de HCT116-cellijn uitgevoerd met behulp van bepaalde kleine interfererende RNA’s, terwijl de effectiviteit van de neerwaartse regulatie werd geverifieerd door reverse transcriptie-kwantitatieve PCR en immunofluorescentie.

Sferoïde-vormingstest werd uitgevoerd met behulp van ultra-lage bevestigingsplaten. De IHC- resultaten bevestigden dat SOX9 was opgereguleerd bij patiënten met stadium II (91%) en superieure T3-stadium (67%) CC. Merkwaardig , groter is SOX9 expressie betrekking op medische stadium tumor meet- en tumor locatie. Bovendien was verhoogde SOX9-expressie aanwezig in recidiverende omstandigheden met inheemse tumoren ; niettemin , Het was niet gerelateerd aan een verhoogde overleving waarschijnlijkheid .

Multiple organ tumor tissue array
MC964b	TissueArray	each	EUR 306
Description: Multiple organ tumor tissue array, including TNM, clinical stage and pathology grade, 96 cases/96 cores, replacing MC964a

Multiple organ tumor tissue array
TP481a	TissueArray	each	EUR 198
Description: Multiple organ tumor tissue array, including pathology grade, TNM and clinical stage (reference AJCC 7th version), 48 cores/48 cores, replacing TP481

Multiple kidney cancer with matched kidney tissue array
KD461	TissueArray	each	EUR 258
Description: Multiple kidney cancer with matched kidney tissue array, including pathology grade, TNM and clinical stage, 23 cases/46 cores

Kidney tumor tissue array with matched tumor adjacent kidney tissue
KD2602a	TissueArray	each	EUR 354
Description: Kidney tumor tissue array with matched tumor adjacent kidney tissue, including TNM, clinical stage and pathology grade, 65 cases/260 cores, replacing KD2602

Multiple types of kidney cancer tissue array
KD1502	TissueArray	each	EUR 258
Description: Multiple types of kidney cancer tissue array, including TNM, clinical stage and pathology grade, 75 cases/150 cores

Multiple normal organ tissue with tumor tissue array
BCN911	TissueArray	each	EUR 306
Description: Multiple normal organ tissue with tumor tissue array, including pathology grade, TNM and clinical stage (AJCC 8.0), 91 cases/91 cores

Kidney tissue array
KD803b	TissueArray	each	EUR 354
Description: Kidney tissue array, 80 cases/80n cores (core size 1.5mm), replacing KD803a

Multiple organs tumor and normal tissue array
MC1501A	TissueArray	each	EUR 474
Description: Multiple organs tumor and normal tissue array, including TNM, clinical stage and pathology grade, 150 cases/150 cores, replacing BC001134b

Multiple organs tumor and normal tissue array
MC2501	TissueArray	each	EUR 678
Description: Multiple organs tumor and normal tissue array, with TNM, clinical stage and pathology grade, 250 cases/250 cores

Multiple organ tumor with normal tissue array
MC482	TissueArray	each	EUR 198
Description: Multiple organ tumor with normal tissue array, including pathology grade, TNM and clinical stage, 40 cases/48 cores

Multiple organ tumor with normal tissue array
NE921	TissueArray	each	EUR 295
Description: Multiple organ tumor with normal tissue array, 20 cases neuroendocrine tumor) including pathology grade, TNM and clinical stage (small cell carcinoma reference AJCC 8th edition), 46 cases/92 cores (core size 1.5mm)

Multiple stomach tumor with stomach tissue array
ST821	TissueArray	each	EUR 306
Description: Multiple stomach tumor with stomach tissue array, including pathology grade, TNM and clinical stage (reference AJCC 8th version), 80 cases/80 cores

Multiple organ tumor with normal tissue array
T0014b	TissueArray	each	EUR 48
Description: Multiple organ tumor with normal tissue array, including pathology grade, TNM and clinical stage, 6 cases/ 24 cores (1.5mm), replacing T0014a

Multiple testis tumor and testis tissue array
TE482a	TissueArray	each	EUR 168
Description: Multiple testis tumor and testis tissue array, including TNM and clinical stage, 24 cases/48 cores, replacing TE482

Multiple Tumor Tissue Array - Bladder, Colon, Kidney, Lung, Stomach, and Uterus tumors
T8235716d-2	Biochain	2 slides	EUR 368.4
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool.

Multiple kidney disease with kidney tissue array (2016/ISUP WHO classification
KD804a	TissueArray	each	EUR 258
Description: Multiple kidney disease with kidney tissue array (2016/ISUP WHO classification, Grade mean Isup Grade), including pathoogy grade, TNM and clinical stage (reference AJCC 8th version), 75 cases/80 cores, replacing KD804

Multiple organ tumor tissue array with adjacent normal tissue
MC803b	TissueArray	each	EUR 336
Description: Multiple organ tumor tissue array with adjacent normal tissue, including TNM and clinical stage, 40 cases/80 cores, replacing MC803a

Multiple organs neuroendocrine tumor tissue array with normal tissue
NE841	TissueArray	each	EUR 354
Description: Multiple organs neuroendocrine tumor tissue array with normal tissue

Multiple lymphoma tissue array
LM241b	TissueArray	each	EUR 66
Description: Multiple lymphoma tissue array, 12 cases/24 cores (core size 1.0mm), replacing LM241

Multiple cancer tissue array
MC801	TissueArray	each	EUR 306
Description: Multiple cancer tissue array, replacing BC00012, 80 cases/80 cores, with grade information

Kidney tumor tissue array with normal tissue as control
KD961	TissueArray	each	EUR 258
Description: Kidney tumor tissue array with normal tissue as control, including TNM, clinical stage and pathology grade, 48 cases/96 cores

Multiple Kidney cancer test tissue array with unmatched normal adjacent tissue
KD242	TissueArray	each	EUR 48
Description: Multiple Kidney cancer test tissue array with unmatched normal adjacent tissue, 10 cases/24 cores

Multiple Kidney cancer tissue array with normal tissue control from autopsy
KD483	TissueArray	each	EUR 168
Description: Multiple Kidney cancer tissue array with normal tissue control from autopsy, 48 cases/48 cores, with stage and grade data

Kidney cancer tissue array
BC07014b	TissueArray	each	EUR 168
Description: Kidney cancer tissue array, including pathology grade, TNM and clinical stage, 72 cases/72 cores, replacing BC07014a

Kidney cancer tissue array
KD245	TissueArray	each	EUR 66
Description: Kidney cancer tissue array, including TNM, clinical stage and pathology grade, 24 cases/ 24 cores

Kidney cancer tissue array
KD485	TissueArray	each	EUR 168
Description: Kidney cancer tissue array, with normal tissue, including TNM and pathology grade, 48 cases/48 cores

Normal kidney tissue array
KD803	TissueArray	each	EUR 354
Description: Normal kidney tissue array, replacing BN07012, 80 cases/80 cores

Normal kidney tissue array
KDN242	TissueArray	each	EUR 72
Description: Normal kidney tissue array, 24 cases/24 cores

Multiple organ tumor with neuroendocrine differentiation tissue array
BC01072	TissueArray	each	EUR 270
Description: Multiple organ tumor with neuroendocrine differentiation tissue array, including pathology grade, TNM and clinical stage, 36 cases/72 cores

Multiple organ tumor with adjacent normal tissue array
BCN721b	TissueArray	each	EUR 270
Description: Multiple organ tumor with adjacent normal tissue array, including pathology grade, TNM and clinical stage, replaing BCN721a

Multiple organ tumor and adjacent normal tissue array
BCN963b	TissueArray	each	EUR 258
Description: Multiple organ tumor and adjacent normal tissue array, including pathology grade, TNM and clinical stage, 81 cases/96 cores, replacing BCN963a

Multiple organ tumor with adjacent normal tissue array
CM241a	TissueArray	each	EUR 66
Description: Multiple organ tumor with adjacent normal tissue array, including pathology grade, TNM and clinical stage (reference AJCC 7th version), 12 cases/24 cores, replacing CM241

Immune multiple organs tumor and normal tissue array
MC1081	TissueArray	each	EUR 414
Description: Immune multiple organs tumor and normal tissue array, containing 20 cases leukemia, 20 cases non-Hodgkin's lymphoma, 20 cases Hodgkin's lymphoma, 11 cases plasma cell myeloma, 9 cases extramedullary plasmacytoma, 20 cases malignant thymoma, plus 2 each cases of normal lymph node, spleen, bone marrow and thymus gland tissue, 108 cases/108 cores,

Multiple organ tumor with adjacent normal tissue array
MC486	TissueArray	each	EUR 270
Description: Multiple organ tumor with adjacent normal tissue array, including pathology grade, TNM and clinical stage, 48 cases/48 cores, replacing BC00116

Multiple tumor of pancreas and pancreas tissue array
T142c	TissueArray	each	EUR 66
Description: Multiple tumor of pancreas and pancreas tissue array, including pathology grade, TNM and clinical stage, 12 cases/24 cores, replacing T142b

Multiple Species Tissue Slides - Kidney Tissue
10-400-MSTA	ProSci	1 pack	EUR 241.8
Description: The Multiple Species Tissue Array (MSTA) slides were designed to study protein expression patterns in different cells and tissues from multiple species. Tissue slices from three different species are mounted on each MSTA slide which can then be treated as a single histological slide for H&E staining, immunohistochemistry, or in situ hybridization. This format allows a rapid analysis of protein expression and localization across different species. MSTA slides can also be used to quickly determine the species reactivity of a given antibody.

Multiple types skin tumor with matched tumor adjacent tissue array
SK801d	TissueArray	each	EUR 258
Description: Multiple types skin tumor with matched tumor adjacent tissue array, including pathology grade, TNM and clinical stage, 70 cases/80 cores (cores size 1.5mm), replacing SK801c

Kidney cancer tissue array with normal Kidney tissue
KD2082a	TissueArray	each	EUR 474
Description: Kidney cancer tissue array with normal Kidney tissue, including TNM and pathology grade, 96 cases/192 cores, replacing KD2082

Kidney cancer with kidney tissue test tissue array
T071b	TissueArray	each	EUR 48
Description: Kidney cancer with kidney tissue test tissue array, including pathology grade, TNM and clinical stage, 6 cases/24 cores, replacing T071a

Multiple organ cancer tissue array
BC000111b	TissueArray	each	EUR 168
Description: Multiple organ cancer tissue array, including TNM, clinical stage and pathology grade, 39 cases/39 cores, replacing BC000111a

Multiple organ cancer tissue array
BC000119b	TissueArray	each	EUR 546
Description: Multiple organ cancer tissue array, including pathology grade, TNM, clinical stage, Gleason grade and Gleason score, 190 cases/190 cores, replacing BC000119a

Multiple organ cancer tissue array
BC000120b	TissueArray	each	EUR 546
Description: Multiple organ cancer tissue array, including pathology grade, TNM and clinical stage, 190 cases/190 cores, replacing BC000120a

Multiple organ normal tissue array
BN00011b	TissueArray	each	EUR 168
Description: Multiple organ normal tissue array, 44 cases/48 cores, replacing BN00011a

Multiple normal organ tissue array
BN114c	TissueArray	each	EUR 168
Description: Multiple normal organ tissue array, 40 cases/48 cores, replacing BN114b

Multiple organ normal tissue array
BN117a	TissueArray	each	EUR 168
Description: Multiple organ normal tissue array, 45 cases/45 cores, replaced by BN117b

Multiple organ normal tissue array
BN117b	TissueArray	each	EUR 168
Description: Multiple organ normal tissue array, 37 cases/45 cores, replacing BN117a

Multiple organ normal tissue array
BN119a	TissueArray	each	EUR 66
Description: Multiple organ normal tissue array, 17 cases/19 cores, replacing BN119

Multiple organ normal tissue array
BN126	TissueArray	each	EUR 270
Description: Multiple organ normal tissue array, replacing BN113, 45 cases/45 cores

Multiple organ normal tissue array
BN129a	TissueArray	each	EUR 168
Description: Multiple organ normal tissue array, 34 cases/48 cores, replacing BN129

Multiple organ normal tissue array
BN151	TissueArray	each	EUR 78
Description: Multiple organ normal tissue array, 15 case/15 cores, replacing MNC151

Multiple organ normal tissue array
BN242d	TissueArray	each	EUR 66
Description: Multiple organ normal tissue array, 11 cases/24 cores, replacing BN242c

Multiple organ normal tissue array
BN243d	TissueArray	each	EUR 78
Description: Multiple organ normal tissue array, 12 cases/24 cores, replacing BN243c

Multiple organ normal tissue array
BN483b	TissueArray	each	EUR 168
Description: Multiple organ normal tissue array, 24 cases/ 48 cores, replacing BN483a

Multiple organ normal tissue array
BN484	TissueArray	each	EUR 234
Description: Multiple organ normal tissue array, 24 cases/48 cores

Multiple organ normal tissue array
BN501a	TissueArray	each	EUR 168
Description: Multiple organ normal tissue array, 50 cases/50 cores, replacing BN501

Multiple organ normal tissue array
BN961b	TissueArray	each	EUR 306
Description: Multiple organ normal tissue array, 24 cases/96 cores, replacing BN961a

Multiple lung cancer tissue array
LC20813c	TissueArray	each	EUR 546
Description: Multiple lung cancer tissue array, including pathology grade, TNM and clinical stage, 192 cases/192 cores, replacing LC120813b

Multiple lung cancer tissue array
LC20815a	TissueArray	each	EUR 546
Description: Multiple lung cancer tissue array, including pathology grade, TNM and clinical stage (small cell carcinoma is referenced AJCC 8th version), 208 cases/208 cores, replacing LC20815

Multiple organ normal tissue array
MBN111	TissueArray	each	EUR 78
Description: Multiple organ normal tissue array, 11 cases/11 cores

Multiple organ cancer tissue array
MC543	TissueArray	each	EUR 354
Description: Multiple organ cancer tissue array, including TNM and pathology grade, 54 cases/ 54 cores

Multiple organ leiomyosarcoma tissue array
SO8013	TissueArray	each	EUR 258
Description: Multiple organ leiomyosarcoma tissue array, including TNM and pathology grade, 80 cases/ 80 cores

Multiple tumor tissue array covers 53 types of benign
BCN1021	TissueArray	each	EUR 266
Description: Multiple tumor tissue array covers 53 types of benign, malignant, regional lymph node and distant metastasis tumors with normal tissues as controls, including pathology grade, TNM/Stage (AJCC 8th edition), 102 cases/102 cores (core size 1.5mm)

Multiple head and neck tumor with normal tissue array
HN802d	TissueArray	each	EUR 306
Description: Multiple head and neck tumor with normal tissue array, including squamous cell carcinoma, adenoid cystic carcinoma, mucoepidermoid carcinoma, pathology grade, TNM and clinical stage (AJCC 8th edition), 80 cases/80 cores (core size 1.5mm), replacing HN802c

Multiple organ tumor with matched adjacent normal tissue array
MC246b	TissueArray	each	EUR 66
Description: Multiple organ tumor with matched adjacent normal tissue array, including pathology grade, TNM and clinical stage, 12 cases/24 cores, replaced by MC246c

Recent Years Collection Samples. Multiple ovarian tumor tissue array
OV401sur	TissueArray	each	EUR 416
Description: Recent Years Collection Samples. Multiple ovarian tumor tissue array, including survival data, pathology grade, TNM and clinical stage (AJCC 8.0), 20 cases/40 cores (1.5mm)

Kidney carcinoma with matched kidney tissue array
KD244a	TissueArray	each	EUR 48
Description: Kidney carcinoma with matched kidney tissue array, including pathology grade, TNM and clinical stage, 12 cases/24 cores, replacing KD244

Kidney cancer with matched kidney tissue array
KD801a	TissueArray	each	EUR 258
Description: Kidney cancer with matched kidney tissue array, including pathology grade, TNM and clinical stagr, 40 cases/80 cores, replacing KD801

Kidney cancer tissue array with adjacent normal kidney tissue
BC07015b	TissueArray	each	EUR 168
Description: Kidney cancer tissue array with adjacent normal kidney tissue, including TNM, clinical stage and pathology grade, 72 cases/72 cores, replacing BC07015a

Kidney cancer survey tissue array
KD2085	TissueArray	each	EUR 474
Description: Kidney cancer survey tissue array, no overlapping with KD2089, including TNM, clinical stage and pathology grade, 104 cases/208 cores

Kidney cancer survey tissue array
KD2089	TissueArray	each	EUR 474
Description: Kidney cancer survey tissue array, no overlapping with KD2085, including TNM and pathology grade, 104 cases/208 cores

Kidney cancer test tissue array
T072b	TissueArray	each	EUR 48
Description: Kidney cancer test tissue array, with normal control tissue, including TNM, clinical stage and pathology grade, 12 cases/24 cores, replacing T072a

Rat normal kidney tissue array
TR071a	TissueArray	each	EUR 48
Description: Rat normal kidney tissue array, 6 cases/24 cores, replacing TR071

Multiple Tumor Tissue Array - Ovary, Bladder, Breast, Kidney, Uterus, and Lung tumors, plus 12 tumor/normal pairs
T8235714d-2	Biochain	2 slides	EUR 368.4
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool.

Multiple Tumor Tissue Array - Ovary, Bladder, Breast, Kidney, Uterus, and Lung tumors, plus 12 tumor/normal pairs
T8235714d-5	Biochain	5 slides	EUR 694.8
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool.

Multiple Tumor Tissue Array - Kidney, Colon, Esophagus, Liver, Rectum and Stomach tumors, plus 12 tumor/normal pairs
T8235715d-2	Biochain	2 slides	EUR 368.4
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool.

Multiple Tumor Tissue Array - Kidney, Colon, Esophagus, Liver, Rectum and Stomach tumors, plus 12 tumor/normal pairs
T8235715d-5	Biochain	5 slides	EUR 694.8
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool.

Multiple Tumor Tissue Array - Bladder, Colon, Kidney, Lung, Stomach, and Uterus tumors, plus 12 tumor/normal pairs
T8235716d-5	Biochain	5 slides	EUR 694.8
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool.

Soft tissue tumor tissue array
BC24011b	TissueArray	each	EUR 270
Description: Soft tissue tumor tissue array, including TNM and clinical stage, 63 cases/63 cores, replacing BC24011a

Soft tissue tumor tissue array
SF961	TissueArray	each	EUR 222
Description: Soft tissue tumor tissue array, including TNM and clinical stage, 48 cases/96 cores

Kidney Tissue Lysate (Tumor)
1707-01	ProSci	0.1 mg	EUR 336.3
Description: Kidney tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Kidney Tissue Lysate (Tumor)
1707-02	ProSci	0.1 mg	EUR 336.3
Description: Kidney tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Kidney Tissue Lysate (Tumor)
1707-03	ProSci	0.1 mg	EUR 336.3
Description: Kidney tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Kidney Tissue Lysate (Tumor)
1707-04	ProSci	0.1 mg	EUR 336.3
Description: Kidney tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Kidney Tissue Lysate (Tumor)
1707-05	ProSci	0.1 mg	EUR 336.3
Description: Kidney tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Kidney Tissue Lysate (Tumor)
1707-06	ProSci	0.1 mg	EUR 336.3
Description: Kidney tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Kidney Tissue Lysate (Tumor)
1707-07	ProSci	0.1 mg	EUR 336.3
Description: Kidney tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Kidney Tissue Lysate (Tumor)
1707-08	ProSci	0.1 mg	EUR 336.3
Description: Kidney tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Kidney Tissue Lysate (Tumor)
1707-09	ProSci	0.1 mg	EUR 336.3
Description: Kidney tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Kidney Tissue Lysate (Tumor)
1708-01	ProSci	0.1 mg	EUR 336.3
Description: Kidney tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Kidney Tissue Lysate (Tumor)
1708-02	ProSci	0.1 mg	EUR 336.3
Description: Kidney tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Kidney Tissue Lysate (Tumor)
1708-03	ProSci	0.1 mg	EUR 336.3
Description: Kidney tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Kidney Tissue Lysate (Tumor)
1709-01	ProSci	0.1 mg	EUR 336.3
Description: Kidney tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Kidney Tissue Lysate (Tumor)
1709-02	ProSci	0.1 mg	EUR 336.3
Description: Kidney tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Kidney Tissue Lysate (Tumor)
1709-03	ProSci	0.1 mg	EUR 336.3
Description: Kidney tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Kidney Tissue Slide (Tumor)
10-402-10um	ProSci	10 um	EUR 241.8

Kidney Tissue Slide (Tumor)
10-402-4um	ProSci	4 um	EUR 216.6

Ovarian tumor tissue array
BC110118	TissueArray	each	EUR 270
Description: Ovarian tumor tissue array, including pathology grade, TNM and clinical stage, 72 cases/72 cores, replacing BC11012

Testis tumor tissue array
BC23012	TissueArray	each	EUR 270
Description: Testis tumor tissue array, 23 cases/63 cores

Brain tumor tissue array
GL2083c	TissueArray	each	EUR 546
Description: Brain tumor tissue array, including pathology grade, 192 cases/192 cores (core size 1.0mm), replacing GL2083b

Brain tumor tissue array
GL242a	TissueArray	each	EUR 270
Description: Brain tumor tissue array, with normal tissue, 2 serial sections, 24 cases/48 cores replacing GL242

Brain tumor tissue array
GL243	TissueArray	each	EUR 198
Description: Brain tumor tissue array, including pathology grade, 24 cases/24 cores

Brain tumor tissue array
GL803d	TissueArray	each	EUR 306
Description: Brain tumor tissue array,including astrocytoma, glioblastoma,oligoastrocytomas,oligodendroglioma,medulloblastoma and ependymoma,80 cases/80 cores (core size 1.5mm), replacing GL803c

Lymphoma tumor tissue array
LY1501	TissueArray	each	EUR 258
Description: Lymphoma tumor tissue array, 75 cases/150 cores

Lymphoma tumor tissue array
LY2088a	TissueArray	each	EUR 546
Description: Lymphoma tumor tissue array, 208 cases/208 cores replacing LY2088

Pancreatic tumor tissue array
PA806	TissueArray	each	EUR 306
Description: Pancreatic tumor tissue array, including TNM and clinical stage, 80 cases/ 80 cores

Brain tumor tissue array
T176a	TissueArray	each	EUR 48
Description: Brain tumor tissue array, including pathology grade, 6 cases/24 cores, replacing T176

Heart tumor tissue array
T301a	TissueArray	each	EUR 48
Description: Heart tumor tissue array, with normal heart tissue, including TNM, 6 cases/24 cores, replacing T301

Uterus tumor tissue array
UT802a	TissueArray	each	EUR 306
Description: Uterus tumor tissue array, including stromal and leiomyo sarcoma, endometrioid adenocarcinoma, chorionepithelioma, hydatidiform mole, clear cell carcinoma, carcinsarcoma, sarcomatoid carcinoma, with pathology grade, TNM/Stage (AJCC 8th edition), 80 cases/80 cores (cores size 1.5mm), replacing UT802

Multiple tumor (24 organs )and normal (6 organs) tissue array
FDA808l-2	TissueArray	each	EUR 306
Description: Multiple tumor (24 organs )and normal (6 organs) tissue array, with grade and TNM/Stage,72 cases/72 cores (core size 1.5mm), replacing FDA808k-2

Multiple ovarian tumor with matched cancer adjacent ovary tissue array
OV901	TissueArray	each	EUR 306
Description: Multiple ovarian tumor with matched cancer adjacent ovary tissue array, including serous carcinoma, clear cell carcinoma, endometrioid adenocarcinoma,mucinous adenocarcinoma,disgerminoma,yolk sac tumor and sertoli-Leydig cell tumors and mixed germ cell tumor,thology grade, TNM and clinical stage (AJCC 8.0), 76 cases/90 cores (1.5mm)

Kidney cancer tissue array with matched cancer adjacent kidney tissue
KD2601a	TissueArray	each	EUR 354
Description: Kidney cancer tissue array with matched cancer adjacent kidney tissue,including TNM, clinical stage and pathology grade, 65 cases/ 260 cores, replacing KD2061

Kidney cancer tissue array with matched adjacent normal kidney tissue
KD901a	TissueArray	each	EUR 258
Description: Kidney cancer tissue array with matched adjacent normal kidney tissue, including TNM, clinical stage and pathology grade, 40 cases/90 cores, replacing KD901

Multiple Species Frozen Tissue Array - Brain
T6134035-1	Biochain	1 slide	EUR 264
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool.

Multiple Species Frozen Tissue Array - Brain
T6134035-5	Biochain	5 slides	EUR 804
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool.

Multiple Species Frozen Tissue Array - Liver
T6134149-1	Biochain	1 slide	EUR 264
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool.

Multiple Species Frozen Tissue Array - Liver
T6134149-5	Biochain	5 slides	EUR 804
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool.

Multiple Species Paraffin Tissue Array - Brain
T8134035-2	Biochain	2 slides	EUR 298.8
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool.

Multiple Species Paraffin Tissue Array - Brain
T8134035-5	Biochain	5 slides	EUR 540
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool.

Multiple Species Paraffin Tissue Array - Liver
T8134149-2	Biochain	2 slides	EUR 298.8
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool.

Multiple Species Paraffin Tissue Array - Liver
T8134149-5	Biochain	5 slides	EUR 540
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool.

Normal gastric tissue array (multiple parts)
BN01013b	TissueArray	each	EUR 198
Description: Normal gastric tissue array (multiple parts), 72 cases/72 cores, replacing BN01013a

Multiple types breast cancer tissue array
BR1003a	TissueArray	each	EUR 306
Description: Multiple types breast cancer tissue array, including pathology grade, TNM and clinical stage, 47 cases/101 cores, replacing BR1003

Multiple organ lymph node tissue array
LN802a	TissueArray	each	EUR 270
Description: Multiple organ lymph node tissue array, 80 cases/80 cores, replacing LN802

Multiple diseases of liver tissue array
LV1201b	TissueArray	each	EUR 474
Description: Multiple diseases of liver tissue array, includin pathology grade, TNM and clinical stage, 118 cases/120 cores, replacing LV1201a

Multiple cancer (3 types) tissue array
MC243b	TissueArray	each	EUR 108
Description: Multiple cancer (3 types) tissue array, including TNM, clinical stage and pathology grade, 24 cases/ 24 cores, replacing MC243a

Multiple organ metastatic carcinoma tissue array
MET961b	TissueArray	each	EUR 300
Description: Multiple organ metastatic carcinoma tissue array, including pathology grade, 48 cases/96 cores, replacing MET961a

Mouse multiple organ normal tissue array
MO1601b	TissueArray	each	EUR 270
Description: Mouse multiple organ normal tissue array, 160 cases/160 cores, replacing MO1601a

Mouse multiple organ normal tissue array
MO541e	TissueArray	each	EUR 138
Description: Mouse multiple organ normal tissue array, 10 cases/54 cores, replacing MO541d

Multiple organ metastatic cancer tissue array
MT2081	TissueArray	each	EUR 474
Description: Multiple organ metastatic cancer tissue array, 19 organ/104 cases/208 cores

Multiple organ cancer metastasis tissue array
MT801	TissueArray	each	EUR 306
Description: Multiple organ cancer metastasis tissue array, 80 cases/80 cores (core size 1.5mm)

Bovendien gaf nuttige evaluatie aan dat SOX9-silencing de bolvormingsfunctionaliteit van HCT116-cellen aanzienlijk verzwakte. Het huidige onderzoek was de eerste om de expressiebereiken van SOX9 te beoordelen bij Mexicaanse patiënten die werden geïdentificeerd met CC in een vroeg stadium. De bovengenoemde bevindingen gaven aan dat primaire SOX9-expressie een essentiële functie kan spelen bij tumorgenese en gerelateerd kan zijn aan superieure T-stadia van patiënten met klinisch stadium II, maar niet met terugvalvrije overleving.